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We showed previously that ambrisentan, a selective endothelin type
A receptor antagonist, and tadalaﬁl, a PDE5 inhibitor, act synergistically
to relax endothelin-constricted pulmonary arteries (Liang et al. Hyper-
tension 2012; 59: 705-11). To conﬁrm these ﬁndings in an in-vivomodel
of PAH, we investigated the effect of ambrisentan and tadalaﬁl in
combination on hypoxia-induced PAH in rats. Upon exposure to hypoxia
(10% O2), male SD rats were dosed with vehicle, ambrisentan (1 mg/kg,
q.d.), tadalaﬁl (10 mg/kg, q.d.) or the combination via oral gavage for
3 weeks. Three weeks of exposure of rats to hypoxia increased mean
pulmonary arterial pressure (mPAP) from 10.8 &plusmn0.7 mmHg
(normoxic, mean &plusmn SEM, n= 8) to 23.9 &plusmn1.3 mmHg
(hypoxic, n = 12, p b 0.01 vs normoxic). Teatments with ambrisentan,
tadalaﬁl and the combination reducedmPAP to 20.1 &plusmn0.8 mmHg
(n= 12, p b 0.05 vs hypoxic), 20.8 &plusmn1.2 mmHg (n= 11,
p b 0.05 vs hypoxic) and 15.9 &plusmn1.0 mmHg (n= 12, p b 0.01 vs
hypoxic), respectively. Chronic exposure of rats to hypoxia also increased
the ratio of right ventricle weight/ left ventricle weight (RV/LV) from
0.326 &plusmn0.013 (normoxic, n = 8) to 0.602 &plusmn0.019 (hyp-
oxic, n = 12, p b 0.01 vs normoxic). The ratios of RV/LV from hypoxic
rats dosed with ambrisentan, tadalaﬁl and the combination were
decreased to 0.527 &plusmn0.014 (n= 12, p b 0.05 vs hypoxic),
0.531 &plusmn0.016 (n= 11, p b 0.05 vs hypoxic) and 0.430 &plusmn
0.017 (p b 0.01 vs hypoxic). Consistent with the in-vitro pulmonary
artery data, the combination of ambrisentan and tadalaﬁl caused a
greater effect than each drug alone or the calculated sum of the
individual effects of each drug, suggesting that ambrisentan and tadalaﬁl
synergistically attenuate hypoxia-induced PAH in rats.
doi:10.1016/j.lfs.2013.12.158
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Objectives: The currently ongoing DETECT study, a two-stage,
prospective, observational, cohort study in systemic scleroderma (SSc)
patients to evaluate screening tests and the incidence of pulmonary
arterial hypertension (PAH) and pulmonary hypertension, is
attempting to reﬁne the screening process in pulmonary artery
hypertension associated with SSc. We adopted the same multiple
screening tests forced vital capacity [% predicted]/DLCO [% predicted];
current/past telangiectasias; anti-centromere antibody; N-terminal
pro-brain natriuretic peptide; uric acid; right axis deviation on
electrocardiography) in patients with SSc in our hospital to evaluate
its Method: Date from 21 SSC patients, who had undergone right heart
catheterization from 2009 to 2012 in our hospital, were retrospectively
analyzed.We compared the result of DETECT screening system tomean
pulmonary artery pressure assessed by right heart catheterization.
Results: Seventeen SSc patients (80.9%) were categorized as candidates
to referral to right heart catheterization in this study. Overall sensitivity
was 100% and speciﬁcity was 25%. Conclusion: According to the 2012
American College of Rheumatology Annual Meeting, DETECT algorithm
was announced that its sensitivity was 96% and speciﬁcity was 48%.
Therefore, our results indicated that DETECT algorithm had the
possibility to overestimate the risk of PAH in SSc patients.
doi:10.1016/j.lfs.2013.12.159
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There is increased risk of pulmonary hypertension (PH) in
patients with Atrial Septal Defect (ASD), although the factors
associated have not been clearly deﬁned. Endothelin-1 (ET-1), a
potent vasoconstrictor derived mainly from pulmonary endothelium,
has been reported to be elevated in PH associated with congenital
heart defect (CHD). However, studies about CHD-related PH included
only a small number of ASD-patients and most of them were
performed in children. In this study, we aim to measure the
circulating ET-1 level in adult patients with uncorrected ASD
complicated by severe pulmonary hypertension. Fifty-two newly
diagnosed ASD patients were participating in this study, aged 20–
79 years old. Measurements of RVSP, characteristics of ASD, remod-
eling RV were performed using TTE and TEE. The hemodynamic
measurement by echo showed signiﬁcant correlation with right
heart catheterization (r = 0.8;p b 0.0001). Peripheral blood was
withdrawn from brachialis vein and circulating ET-1 was measured
using ELISA. Severe PH were deﬁned as RVSP N 60 mmHg. The severe
PH group (n = 25) was conﬁrmed by larger RA diameter, larger RV
diameter, reduced RV systolic function, and higher tricuspid valve
gradient as compared to non-severe PH group (n = 27) (47.6 ± 1.47
vs. 41.2 ± 1.24 mm; p b 0.01; 48.6 ± 1.16 vs. 41.2 ± 1.29 mm;
p b 0.001; 21.9 ± 1.01 vs. 25.9 ± 1.45 mm; p b 0.0001; 92 ± 5.5 vs.
33.7 ± 1.88 mmHg; p b 0.0001; respectively). There were no differ-
ences of age, diameter of the defect, and pulmonary ﬂow ratio in the
severe PH group. Interestingly, the circulating plasma ET-1 level was
signiﬁcantly lower in the severe group (6.3 ± 0.48 vs. 4.7 ± 0.32 pg/dl;
p b 0.01). In conclusion, we reported lower circulating plasma ET-1 in
ASD patients with severe PH. Further study should be performed to
elucidate the ET-1 level in pulmonary circulation in this disease.
doi:10.1016/j.lfs.2013.12.160
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Background: Endothelin receptor antagonist (ERA) is recom-
mended for treatment of pulmonary arterial hypertension (PAH).
However, recommendation is based on reports of monotherapy.
Method: We examined consecutive 112 patients diagnosed with
Group 1 and 1' PAHwho visited 14 afﬁliated hospitals from July 2006
to January 2013. The difference in mortality between monotherapy
group and combination therapy group (ERA and other PAH drugs)
was compared. Results: There were 41 idiopathic, 43 collagen
tissue disease, 24 congenial heart disease and 4 other types of PAH.
Mean age was 52.2 years old, female 66.1%, WHO Functional
Class1 5.6%, 2 31.5%, 3 53.9%, 4 9.0%, BNP 128 (49.3–406.5) pg/mL,
cardiac index 3.4 ± 1.6 (L/kg/m2), mean pulmonary arterial pressure
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48.2 ± 19.3 mmHg, and tricuspid regurgitation pressure gradient
(TRPG) 57.5 ± 25.2 mmHg. Pericardial effusion was observed in 28%.
ERA, prostacyclin, PDE-5 inhibitor and epoprostenolwere used in 71.8%,
60.9%, 51.8%, and 18.2%, respectively. There were no signiﬁcant
difference in characteristics between the monotherapy group and the
combination therapy group, except for the frequent use of the
combination therapy in idiopathic PAH. Although pericardial effusion,
cardiac index, and mean right atrial pressure were predictors for
mortality in the combination group, there was no difference in
mortality between themonotherapy group and the combination group.
Conclusion: Combination therapy was frequently used in idiopathic
PAH. However, difference in mortality was not apparent between
monotherapy and combination therapy with other PAH drugs.
doi:10.1016/j.lfs.2013.12.161
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Background: A development of the drugs used in pulmonary
hypertension (PH) contributes a lot to its clinical improvement. An
advent of new endothelin receptor blocker, ambrisentan, has further
diversiﬁed selection of PH drugs. Purpose: The purpose of this study
was to evaluate the efﬁcacy and safety of ambrisentan on PH. Method:
Ambrisentan was administered to 26 (50 ± 19 years old, 7 men, 19
women) patients with PH including 11 patients with chronic throm-
boembolic PH (CTEPH), 5 with Eisenmenger syndrome, 5 with
connective tissue disease (CTD) PH and 3 with idiopathic pulmonary
arterial hypertension. Ambrisentan was added to the other PH drugs in
all the patients. The patients underwent right-side heart catheterization
before and after the administration of ambrisentan with measurement
of cardiac output (CO), mean right atrial pressure (mRA), mean
pulmonary arterial pressure (mPA), pulmonary vascular resistance
(PVR). Brain natriuretic peptide (BNP) was also determined. Results:
After administration of ambrisentan (the average follow-up period was
168 ± 97 days), mPA (36 ± 9 vs 22± 6: p b 0.01) and PVR (11 ± 6 vs.
7 ± 4: p b 0.01) and CO (4.0 ± 1.5 vs. 4.8 ± 1.8: p b 0.05) improved
signiﬁcantly, but BNP, mRA nor heart rate did not. The most frequent
adverse reactions was edema with 6 patients, 3 of which abandoned
ambrisentan. Conclusions: Ambrisentan is useful for pulmonary
hypertension even if added to other PH drugs.
doi:10.1016/j.lfs.2013.12.162
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Introduction: Chronic thromboembolic pulmonary hypertension
(CTEPH) is a serious devastating disease. It is still a challenge to treat
some patients who are not eligible for pulmonary endarterectomy.
Short-term bosentan or PDE5 inhibitor was signiﬁcantly improved in
symptoms, hemodynamics and exercise capacity in such patients.
However, the long-term beneﬁcial effect of advanced pulmonary
vasodilating drugs is little understood. Therefore, we investigated the
long-term effect of advanced therapy in the patients with inoperable
CTEPH retrospectively. Methods and results: All consecutive 7 Japanese
patients (5 female, mean age 62.6 ± 6.9 years) treated with bosentan
(125–250 mg) for symptomatic inoperable CTEPH were included. The
time to clinicalworsening (TCW)was examined (mean follow-up period
896 ± 564 days). WHO-FC was signiﬁcantly improved from 3.1 ± 0.4 to
2.1 ± 0.4 (p b 0.01). Pulmonary vascular resistance was signiﬁcantly
decreased from 786.9 ± 300.0 to 352.2 ± 210.7 dyn s cm−5 (p b 0.05).
Mean pulmonary artery pressure and cardiac index were improved
from 47.0 ± 7.6 to 43.3 ± 5.0 mmHg and from 2.18 ± 0.39 to 3.02 ±
0.74 l/min/m2 (n= 3, follow-up 651–849 days). Six-minute walk dis-
tance was increased from 257.0 ± 151.0 to 369.8 ± 85.7 m (p= 0.06,
n = 4, follow-up 651–931 days). Plasma BNP level was signiﬁcantly
decreased from 1160.0 ± 971.4 to 305.1 ± 285.9 pg/ml (p b 0.05). None
of themwere required hospitalization. Conclusions: Long-term advanced
therapy with bosentan improves symptoms, hemodynamics and TCW in
CTEPH patients. Advanced therapy is proposed as an essential treatment
for the patients with inoperable CTEPH.
doi:10.1016/j.lfs.2013.12.163
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Background: A recently developed mouse model for PAH combines
hypoxia with a VEGF receptor blocker. Herein we aim to describe in
detail this model. The TGFβ/Smad3 pathway is a pivotal factor
regulating the transcription of the endothelin (ET-1) gene. Besides,
interleukin-1β (IL-1β) increases expression of ET-1, and ETA receptor
and reduces expression of ETB receptor. Methods and results: We
placed 3-week old male SV129 mice under hypoxia (O2 = 10%) and
treated themwith a vascular endothelial growth factor receptor blocker
(SU5416) (SU mice) (subcutaneous injection three times a week,
20 mg/kg) for 3 weeks. Compared tomice under hypoxia alone (H) and
control mice (CTRL), these mice developed severe PAH, characterized
by increased right ventricular systolic pressure measured in anesthe-
tized mice by subxiphoid approach (SU: 37 ± 1.7; H: 29 ± 1.4,
CTRL: 22.5 ± 1mmHg), right ventricularhypertrophy (Fulton index: SU:
0.55 ± 0.042; H: 0.4 ± 0.04, CTRL:0.31 ± 0.026) and muscularization
of precapillary vessels together with proliferation of endothelial cells
of small arterioles (PCNA positive on endothelial layer/arterial
section = SU: 2.9 ± 0.25; H: 1 ± 0.13; CTRL: 0.7 ± 0.08), which
lead to completely occluded arterioles by von Willebrand factor
expressing cells. Increased ET-1 mRNA, ETA receptor mRNA, protein
expression and immunostaining signals and reduced ETB receptor
mRNA expression were observed in SU mice only. This was
associated with an increased abundance of phosphorylated Smad3
and a 9-fold increase of IL-1β expression. TGF-β mRNA in H and SU
mice was similar. Conclusion: In severe PAH, Smad3 by potentiating
TGF-β and IL-1β might disturb the expression of the ET system and
may represent therefore potential therapeutic targets.
doi:10.1016/j.lfs.2013.12.164
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